Get started
Author

Furong Du

Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing.
2021 · Weiquan Gu, Jie Yang, et al. · PubMed Central · 45
Association of smoking, alcohol, and coffee consumption with the risk of ovarian cancer and prognosis: a mendelian randomization study
2023 · Sicong Liu, Songwei Feng, et al. · BMC Cancer · 34
PDF
Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis
2022 · Nanya Wang, Yong Qin, et al. · Gene · 24
In Situ Nanofiber Formation Blocks AXL and GAS6 Binding to Suppress Ovarian Cancer Development
2024 · Han Yin, Yue Hua, et al. · Advanced Materials · 22
PDF
Is it beneficial for patients with pT1‐2N1M0 breast cancer to receive p ostmastectomy radiotherapy? An analysis based on RecurIndex assay
2021 · Lina Zhang, Mengli Zhou, et al. · International Journal of Cancer · 17
PDF
An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer
2023 · Tianli Hui, Sainan Li, et al. · The Oncologist · 9
PDF
TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
2022 · Tianzhu Qiu, Xiaoxuan Wang, et al. · World Journal of Surgical Oncology · 7
PDF
Case Report: Identification of a Novel GNAS Mutation and 1p/22q Co-Deletion in a Patient With Multiple Recurrent Meningiomas Sensitive to Sunitinib
2021 · Weiping Hong, Changguo Shan, et al. · Frontiers in Oncology · 7
PDF
Development of a 4-miRNA prognostic signature for endometrial cancer
2022 · Jiazhen Huang, Furong Du, et al. · Medicine · 6
Concordance of RT-qPCR with immunohistochemistry and its beneficial role in breast cancer subtyping
2023 · Yilun Li, Tinghao Chen, et al. · Medicine · 5
Patient-derived tumor organoids for new drug development: promises and challenges
2026 · Meijun He, Ying Wu, et al. · Investigational New Drugs · 3
PDF
CXCL13 shapes tumor immune microenvironment in ovarian cancer with homologous recombination deficiency
2023 · Yue Ding, Zheng Ye, et al. · Genes & Diseases · 3
An extremely rare case of Rosai-Dorfman disease in the spleen
2021 · Xuewu Yang, Chuang Fang, et al. · BMC Surgery · 3
PDF
RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
2022 · Haibo Wang, Li Ma, et al. · Frontiers in Oncology · 2
PDF
Coculture of tumor organoids with pathogenic microorganisms: a novel system to mimic in vivo pathogenic infection
2025 · Xue Zhang, Shulan Sun, et al. · Frontiers in Cellular and Infection Microbiology · 1
Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology
2026 · Jingzhen Zhu, Sheng Wang, et al. · Frontiers in Oncology
PDF
Development and Application of Tumor Organoids: An Emerging Platform for Gynecological Cancers
2025 · Yu Hu, Wei Chen, et al. · International Journal of Women s Health
PDF
Gene expression comparison between primary aggressive luminal breast cancer and paired axillary and sentinel lymph node metastasis.
2023 · Jiyu Li, Xiao Chen, et al. · Journal of Clinical Oncology
PDF
Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Suspected Cryptococcal Meningitis: A Single-Center Clinical Study
2023 · Min Zhang, Jiayang Fang, et al. · SSRN Electronic Journal
Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in HER2-positive early breast cancer
2022 · Yikun Kang, Keyu Chen, et al. · Research Square
PDF
Clinical applicability of targeted next-generation sequencing for precision medicine in diffuse large B-cell lymphoma.
2022 · Dehong Huang, Yao Liu, et al. · Journal of Clinical Oncology
Works count: 23
Citation count: 188
H-index: 7
I10-index: 5
Year
Topic
Type